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Abstract
The use of vascular occlusion during liver resection is still a matter of debate. The aim of this review was
to assess the advantages and disadvantages of portal triad occlusion as a protective strategy during
elective liver resection and liver transplantation. Newer strategies such as pharmacological precondition-
ing are also discussed. A systematic literature search was conducted to detect randomized controlled
trials assessing the effectiveness and safety of portal triad clamping, ischaemic preconditioning and
pharmacological preconditioning during liver surgery. Vascular clamping cannot be systematically rec-
ommended. When used, portal triad clamping is associated with a tendency towards reduced blood loss
and blood transfusion without having an impact on morbidity. Intermittent clamping appears to be better
tolerated than continuous clamping, especially in patients with chronic liver disease. Ischaemic precon-
ditioning before continuous portal triad clamping reduces reperfusion injury after warm ischaemia,
particularly in steatotic patients. Ischaemic preconditioning has unclear effects in transplantation and
there is currently no evidence to support or refute the use of ischaemic preconditioning in the donor. There
are emerging alternative conditioning strategies, including the use of volatile anaesthetics, which may
provide new and easily applicable therapeutic options to protect the liver.
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Introduction
Over the past two decades, liver resection has increasingly been
performed worldwide because of improved post-operative out-
comes and evidence that this approach offers the only chance of
cure in many patients.1–4 Technical innovations have mainly
focused on minimizing bleeding during transection of the hepatic
parenchyma5,6 as excessive haemorrhage and the need for blood
transfusion are associated with increased post-operative morbid-
ity and mortality,7 as well as reduced long-term outcome.7–9 Portal
triad clamping (Pringle manoeuver) has been used since the
early 20th century10 to prevent bleeding during parenchyma
transection.11–14 The concomitant use of low central venous pres-
sure (CVP) anaesthesia further minimizes blood loss by prevent-
ing retrograde bleeding from the hepatic veins.15,16
However, the Pringle manoeuver causes ischaemic injury to the
remaining liver with a risk of poor post-operative outcome.12,17
Diseased livers with steatosis or fibrosis poorly tolerate reperfu-
sion injury and can develop liver failure even after short periods of
ischaemia.18 Various methods have been attempted to decrease the
reperfusion injury associated with prolonged duration of vascular
occlusion including intermittent clamping, ischaemic precondi-
tioning and more recently pharmacological preconditioning.
Intermittent clamping consists of repeated periods of clamping
followed by short periods of reperfusion.19–21 However, the ben-
efits of intermittent clamping are debatable, as it may lead to
multiple reperfusion events with potentially repetitive hepatocel-
lular damage, bleeding during reperfusion episodes and a pro-
longed operating time. Ischaemic preconditioning consists of a
brief period of ischaemia and reperfusion applied prior to the
prolonged ischaemic insult (10 min of ischaemia and 10 min of
reperfusion).22,23 Finally, pharmacological preconditioning with a
volatile anaesthetic is a new approach in liver surgery. It has been
shown in a rat model24 and in a clinical study25 that the application
DOI:10.1111/j.1477-2574.2009.00066.x HPB
HPB 2009, 11, 290–295 © 2009 International Hepato-Pancreato-Biliary Association
of isoflurane before induction of hepatic ischaemia protected the
liver from ischaemia/reperfusion injury.
The aim of the review was to assess the advantages and disad-
vantages of hepatic vascular occlusion as a protective strategy
during elective liver resection and liver transplantation. New
strategies such as pharmacological preconditioning will also be
discussed.
Methodology
An electronic search of Medline was undertaken to identify com-
parative randomized controlled trials (RCT) and meta-analyses
regarding the subject. The terms ‘vascular occlusion’, ‘portal trial
clamping’, ‘liver resection’ and ‘liver transplantation’ were used in
various combinations. The search terms were identified in the
title, abstract, or medical subject heading (MeSH). With a few
exceptions, only original articles published in English until
October 2008 were selected for further analysis. Manual cross-
referencing was also used to find further relevant articles. All
articles were classified according to their level of evidence. The
classification proposed by the Oxford Centre for Evidence-based
Medicine was used to rank each publication and to give the grade
of recommendation (A, B, C, D) based on the available literature
for each topic.26
Portal triad clamping vs. no clamping
There were four RCT comparing clamping vs. no clamping
during elective liver resection (Table 1).20,23,27,28 Three of them
compared intermittent clamping with no clamping, whereas
Chouker et al.23 included patients with continuous clamping.
According to the first three RCT,23,27,28 portal triad clamping was
associated with less intra-operative blood loss, a shorter resec-
tion time and a higher level of post-operative transaminases.
However, Capussotti et al.20 did not confirm these results as no
significant difference was shown between patients with or
without clamping, even in patients with a chronic diseased liver.
The Cochrane meta-analysis published in 2007,29 based on these
RCT, revealed decreased blood loss with vascular clamping but
this difference was not statistically significant. It confirmed a sig-
nificant higher peak of transaminases at post-operative days 1
and 2 associated with vascular clamping. However, there was no
significant difference in terms of post-operative liver function
and morbidity between patients with or without vascular clamp-
ing. The recent meta-analysis by Rahbari et al.30 did not show
any difference in blood loss and post-operative morbidity in
patients undergoing a liver resection with or without portal
triad clamping. However, for methodological reasons, this
meta-analysis did not include the same RCT than the previous
one. Although early studies reported significantly reduced blood
loss with portal triad clamping, more recent studies have not
confirmed this finding. This could be because of technical
advances in hepatic surgery that now permit resection with
limited blood loss, even without hepatic inflow occlusion.
Portal triad clamping: continuous vs.
intermittent
Two RCTs compared continuous and intermittent portal trial
clamping in patients who underwent liver resection (Table 2).19,31
In both studies, intermittent clamping consisted of repeated
periods of 15 min of ischaemia followed by 5-min reperfusion
episodes. In the trial by Capussotti et al.31 all patients suffered
from liver cirrhosis. Belghiti et al.19 demonstrated that blood loss
during liver resection was significantly higher in the intermittent
clamping group. Post-operative transaminase levels were signifi-
cantly higher in the continuous portal triad clamping group
than in intermittent portal triad clamping group when livers
with chronic liver disease were included. Post-operative bilirubin
levels were also significantly higher in the continuous portal
triad clamping group than in the intermittent portal triad
clamping group when cirrhotic livers were included in the analy-
sis. Thus it appears that livers with chronic disease do not tol-
erate continuous vascular clamping as well as normal livers. It
must be noted that the other trial which included only cirrhotic
livers did not find any significant difference in terms of blood
loss, post-operative liver function tests and post-operative mor-
bidity.31 The Cochrane meta-analysis pooled the patients from
the last two RCTs.29 Although blood loss during transection was
significantly less in the continuous clamping group compared
with the intermittent clamping group, there was no significant
difference in the total operative blood loss and transfusion
between both groups. Considering that intermittent portal triad
clamping does not increase the total blood loss, the operating
time and the predisposition of the cirrhotic and steatotic livers
Table 1 Randomized controlled trials comparing portal triad clamp-
ing and no clamping
Author Year No
patients
No clamping vs.
Man et al.27 1997 93 Intermittent clamping
Man et al.28 2003 40 Intermittent clamping
Chouker et al.23 2004 75 Intermittent (n = 25) and
continuous (n = 25)
Capussotti et al.20 2006 126 Intermittent clamping
Table 2 Randomized controlled trials comparing intermittent and
continuous portal triad clamping
Author Year No
patients
Intermittent clamping
Belghiti et al.19 1999 86 15 min/5 min
Capussotti et al.31 2003 35 15 min/5 min (Cirrhotic liver)
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to ischaemic injury, intermittent clamping seems to be better
than continuous clamping at least in patients with chronic liver
disease.
As the optimal ischaemic time during intermittent clamping
remains controversial, Esaki et al. conducted a RCT comparing
the short-term outcome of hepatectomy using intermittent
clamping with an ischaemic interval of 15 vs. 30 min, the duration
of reperfusion being 5 min. There was no significant difference in
the morbidity, blood loss, transfusion requirements, liver function
tests, or hospital stay between the groups. The operating time was
lower in the 30-min group.
Ischaemic preconditioning
In the mid 80s, Murry et al.observed that brief periods of coro-
nary occlusion followed by a short reperfusion before prolonged
ischaemia led to a reduced size of myocardial infarct. This
manipulation, hence termed ischaemic preconditioning,
increased the heart’s tolerance to reperfusion injury after pro-
longed periods of ischaemia. While the liver is prone to ischaemic
injury when the Pringle manoeuver is applied, the incentive to
investigate similar preconditioning was obvious. A common pro-
tocol in the liver consists of 10 min of ischaemia followed by
10 min of reperfusion.33
Clavien et al.34 performed the first study in the human liver. A
twofold reduction of post-operative serum transaminases was
registered. A reduction of apoptotic cells corroborated this
finding. Patients with mild to moderate steatosis with less toler-
ance to ischaemic injury seemed to have even an increased effect.
These findings were reproduced in a prospective randomized set-
ting.22 Additionally, the authors noted that the effect was lost in
patients older than 60 years of age whereas maximal in young
patients. In patients with liver steatosis, and upon inflow occlusion
for >40 min, ischaemic preconditioning demonstrated a particu-
larly strong protective effect. A RCT by Chouker et al.23 comparing
ischaemic preconditioning vs. continuous clamping, showed
improved cardiovascular stability by lowering the need for cat-
echolamines after liver reperfusion. In contrast, a third RCT by
Azoulay et al.35 included 30 individuals in each group but did not
confirm a beneficial effect of ischaemic preconditioning. The
authors found no differences in post-operative serum transami-
nase levels and post-operative morbidity (Table 3). Additionally, a
recent Cochrane analysis observed no statistically significant dif-
ference in the mortality, liver failure, blood loss, or haemodynamic
changes.29 However, intensive care unit stay and hospital stay were
significantly lower in the ischaemic preconditioning group.
Ischaemic preconditioning was also compared with intermit-
tent clamping (Table 4). A RCT by Petrowsky et al.36 showed that
these two protective approaches appear to be equally effective
against liver injury. Furthermore, is that in this study, ischaemic
preconditioning was associated with lower blood loss, lower trans-
fusion amount and shorter transection time. Another study con-
firmed the equality of the two techniques; however, markers
of apoptosis were increased in the preconditioning group if
ischaemia exceeded 40 min.37
The benefit of ischaemic preconditioning in liver transplanta-
tion is ambiguous.38 Several studies found reduced post-
operative serum transaminase levels and a reduction of cell
death markers and inflammatory infiltrates.39–42 However, most
studies do not show a benefit for patient or graft survival.43 In
contrast, one study showed a paradoxical increase in reperfusion
injury.44 The recent meta-analysis by Gurusamy et al.45 found no
statistically significant difference in mortality, delayed graft
function, or primary graft non-function. Currently, no evidence
exists to support or refute ischaemic preconditioning in liver
transplantation.
Pharmacological preconditioning
Pharmacological preconditioning is a promising field, as a variety
of substances proved to be effect in animal experiments. However,
very few concepts have made the transition to the human.
In a recent RCT, 64 patients undergoing liver surgery with
inflow occlusion were randomized to 30 min of intra-operative
preconditioning with sevoflurane or anaesthesia with propofol.25
Thirty minutes before inflow occlusion, propofol was replaced by
sevoflurane in the preconditioning group. Preconditioning with
sevoflurane significantly reduced post-operative aspartate ami-
notransferase (AST) and alanine transaminase (ALT) levels. Fur-
thermore, the overall incidence of postoperative complications
and the number of major events was reduced. This beneficial
effect was stronger in patients with hepatic steatosis. A potential
mechanism may involve the upregulation of iNOS (inducible
nitric oxide synthase), as this enzyme was significantly increased
in the group with sevoflurane.
Table 3 Randomized controlled trials comparing ischaemic precon-
ditioning vs. continuous clamping
Author Year No
patients
Ischaemic preconditioning
Clavien et al.22 2003 100 10 min/10 min/continuous
Chouker et al.23 2004 75 10 min/10 min/continuous
Azoulay et al.35 2006 60 10 min/10 min/vascular
exclusion of the liver
preserving caval flow
Table 4 Randomized controlled trials comparing ischaemic precon-
ditioning with intermittent clamping
Author Year No
patients
Clamping
Petrowsky
et al.36
2006 73 IPC: 10 min/10 min/continuous
vs. intermittent: 15 min/5 min
Smyrniotis
et al.37
2006 54 IPC: 10 min/10 min/continuous
vs. intermittent: 15 min/5 min
IPC, ischaemic preconditioning.
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Another RCT in the transplantation setting from Lang and
colleagues46 supports this hypothesis. During liver transplanta-
tion, patients were randomized to receive a volatile, high but non-
toxic dose of nitric oxide (80 ppm). Inhaled nitric oxide
significantly decreased the length of hospital stay, improved serum
transaminase levels and coagulation times, and reduced the
number of apoptotic hepatocytes.
A small number of clinical trials have addressed other sub-
stances, involved in different mechanisms of hepatic reperfusion
injury.
The synthetic protease inhibitor gabexate mesilate was evalu-
ated in randomized patients undergoing liver surgery.47 Intrave-
nous administration prior to surgery decreased markers of
hepatic injury, serum transaminases and suppressed plasmatic
interleukin-6 levels. A similar effect was shown in a clinical trial,
analysing the effect of pre-operative administration of 500 mg of
methylprednisolone.48 During resection, intra-operative precon-
ditioning with 600 mg of alpha-lipoic acid also reduced markers
of hepatic damage by inflow occlusion.49
Again in the transplant setting, administration of 250 mg of
methylprednisolone prior to organ harvesting significantly ame-
liorated ischemia/reperfusion injury and lowered the incidence of
acute rejection.50 Systemic administration of the pan-caspase
inhibitor IDN6556 reduced post-operative serum transaminase
levels.51 In another study, systemic pre-operative administration of
thymoglobulin decreased ischaemia/reperfusion injury after
orthotopic liver transplantation.52
Conclusions and recommendations
The armamentarium of liver surgeons should contain the
regular vascular clamping methods to reduce blood loss during
complex liver resection or to prevent massive haemorrhage in
cases of accidental injury to major vessels during mobilization of
the liver or during parenchymal transection. Nowadays, thanks
to better knowledge of surgical liver anatomy, to refinements in
surgical techniques and to maintenance of a low CVP during
parenchymal transection, vascular clamping cannot be system-
atically recommended (level A). When used, portal triad clamp-
ing is associated with a tendency towards reduced blood loss
and blood transfusion without impact on morbidity (level A).
Among the different methods of vascular occlusion, intermittent
clamping appears to be better tolerated especially in patients
with chronic liver disease (level A). Ischaemic preconditioning
before continuous portal triad clamping reduces reperfusion
injury after warm ischaemia, particularly in steatotic patients
(level A). Clinically, ischaemic preconditioning and intermittent
clamping are equally effective but in cases of complex liver resec-
tion, where the clamping time could be long, intermittent
clamping must be preferred (level A). Ischaemic preconditioning
has unclear effects in transplantation and there is currently no
evidence to support or refute the use of ischaemic precondition-
ing in donor liver retrievals. There are increasing alternative
conditioning strategies, including the use of volatile anesthetics,
which may provide new and easily applicable therapeutic
options to protect the liver.
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